Advisers let down by MiFID II conflicting cost calculations - Fundscape

Transaction costs should not be considered "in isolation"

Victoria McKeever
clock • 3 min read

Conflicting and "ill-prepared" MiFID II cost calculations have "let advisers and investors down badly", Fundscape chief executive Bella Caridade-Ferreira has said.

On the introduction of transaction cost disclosure, through the second iteration of the Markets in Financial Instruments Directive (MiFID II), Caridade-Ferreira (pictured) said: "Regulators, Authorised Corporate Directors (ACDs) and platforms were ill‐prepared and have let advisers and investors down badly. It's time they got their act together."  "With an utter disregard for common sense that characterised MiFID II's generally inglorious introduction, the regulators provided fund managers with two diametrically opposed calculation methodologies," she said.    ACDs and compliance team...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Investment

Advisers zoomed in on capital accumulation in Q4 2025

Advisers zoomed in on capital accumulation in Q4 2025

Titan Square Mile research finds

Jen Frost
clock 30 January 2026 • 3 min read
Measure for measure: How to track your tracker fund

Measure for measure: How to track your tracker fund

Tracking difference and tracking error

Terry McGivern
clock 28 January 2026 • 3 min read
SJP and AJ Bell pivot from US mega-caps in MPS as concentration woes continue

SJP and AJ Bell pivot from US mega-caps in MPS as concentration woes continue

Healthcare, energy and EM preferred

Linus Uhlig
clock 28 January 2026 • 2 min read